CPRX - Catalyst Pharmaceuticals Board Member Sold $86K In Company Stock | Benzinga
Revealing a significant insider sell on June 5, Molly Harper, Board Member at Catalyst Pharmaceuticals (NASDAQ:CPRX), as per the latest SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Harper sold 5,333 shares of Catalyst Pharmaceuticals. The total transaction amounted to $86,949.
Catalyst Pharmaceuticals shares are trading down 1.66% at $16.04 at the time of this writing on Thursday morning.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Catalyst Pharmaceuticals: Financial Performance Dissected
Revenue Growth: Catalyst Pharmaceuticals displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 15.4%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
-
Gross Margin: Achieving a high gross margin of 87.29%, ...